In a previous report, proteomic results suggested that ENO1 was prone to oxidation in the cerebral tissue of both 3×Tg-AD mice and AD patients (Shen et al., 2015); such modification might result in the altered metabolic processing of glucose and degradation of Aβ (Butterfield and Lange, 2009). This evidence concerns the gene ENO1 and Alzheimer disease.